Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates

Sigurdur Yngvi Kristinsson, Ola Landgren, S Vincent Rajkumar

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In the twenty-first century, melphalan-prednisone can no longer be regarded as the standard treatment of multiple myeloma patients not eligible for high-dose melphalan followed by autologous stem cell transplantation. The introduction of thalidomide, lenalidomide, and bortezomib has improved the arsenal of therapeutic options in multiple myeloma. Indeed, randomized studies have shown that melphalan-prednisone-thalidomide and melphalan-prednisone- bortezomib are superior to melphalan-prednisone alone. In addition, other combinations, including lenalidomide, are under study. In this review, we discuss the role of novel therapies in multiple myeloma in elderly multiple myeloma patients. Important aspects, such as toxicity and the role of prognostic factors, are also addressed.

Original languageEnglish (US)
Pages (from-to)473-478
Number of pages6
JournalCancer Journal
Volume15
Issue number6
DOIs
StatePublished - Nov 2009

Fingerprint

Melphalan
Multiple Myeloma
Prednisone
Thalidomide
Therapeutics
Stem Cell Transplantation

Keywords

  • Multiple myeloma
  • Prognosis
  • Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates. / Kristinsson, Sigurdur Yngvi; Landgren, Ola; Rajkumar, S Vincent.

In: Cancer Journal, Vol. 15, No. 6, 11.2009, p. 473-478.

Research output: Contribution to journalArticle

Kristinsson, Sigurdur Yngvi ; Landgren, Ola ; Rajkumar, S Vincent. / Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates. In: Cancer Journal. 2009 ; Vol. 15, No. 6. pp. 473-478.
@article{a76a67cec49e416e89e9f3593c125975,
title = "Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates",
abstract = "In the twenty-first century, melphalan-prednisone can no longer be regarded as the standard treatment of multiple myeloma patients not eligible for high-dose melphalan followed by autologous stem cell transplantation. The introduction of thalidomide, lenalidomide, and bortezomib has improved the arsenal of therapeutic options in multiple myeloma. Indeed, randomized studies have shown that melphalan-prednisone-thalidomide and melphalan-prednisone- bortezomib are superior to melphalan-prednisone alone. In addition, other combinations, including lenalidomide, are under study. In this review, we discuss the role of novel therapies in multiple myeloma in elderly multiple myeloma patients. Important aspects, such as toxicity and the role of prognostic factors, are also addressed.",
keywords = "Multiple myeloma, Prognosis, Therapy",
author = "Kristinsson, {Sigurdur Yngvi} and Ola Landgren and Rajkumar, {S Vincent}",
year = "2009",
month = "11",
doi = "10.1097/PPO.0b013e3181c60f08",
language = "English (US)",
volume = "15",
pages = "473--478",
journal = "Cancer Journal (United States)",
issn = "1528-9117",
publisher = "Association Pour le Developpement de la Communication Cancerologique",
number = "6",

}

TY - JOUR

T1 - Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates

AU - Kristinsson, Sigurdur Yngvi

AU - Landgren, Ola

AU - Rajkumar, S Vincent

PY - 2009/11

Y1 - 2009/11

N2 - In the twenty-first century, melphalan-prednisone can no longer be regarded as the standard treatment of multiple myeloma patients not eligible for high-dose melphalan followed by autologous stem cell transplantation. The introduction of thalidomide, lenalidomide, and bortezomib has improved the arsenal of therapeutic options in multiple myeloma. Indeed, randomized studies have shown that melphalan-prednisone-thalidomide and melphalan-prednisone- bortezomib are superior to melphalan-prednisone alone. In addition, other combinations, including lenalidomide, are under study. In this review, we discuss the role of novel therapies in multiple myeloma in elderly multiple myeloma patients. Important aspects, such as toxicity and the role of prognostic factors, are also addressed.

AB - In the twenty-first century, melphalan-prednisone can no longer be regarded as the standard treatment of multiple myeloma patients not eligible for high-dose melphalan followed by autologous stem cell transplantation. The introduction of thalidomide, lenalidomide, and bortezomib has improved the arsenal of therapeutic options in multiple myeloma. Indeed, randomized studies have shown that melphalan-prednisone-thalidomide and melphalan-prednisone- bortezomib are superior to melphalan-prednisone alone. In addition, other combinations, including lenalidomide, are under study. In this review, we discuss the role of novel therapies in multiple myeloma in elderly multiple myeloma patients. Important aspects, such as toxicity and the role of prognostic factors, are also addressed.

KW - Multiple myeloma

KW - Prognosis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=75149132224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75149132224&partnerID=8YFLogxK

U2 - 10.1097/PPO.0b013e3181c60f08

DO - 10.1097/PPO.0b013e3181c60f08

M3 - Article

C2 - 20010166

AN - SCOPUS:75149132224

VL - 15

SP - 473

EP - 478

JO - Cancer Journal (United States)

JF - Cancer Journal (United States)

SN - 1528-9117

IS - 6

ER -